CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 109 enrolled
Drug / intervention
Dupilumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04400318
NCT04400318Phase 4Completed

Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma

Sanofi·interventional·Posted May 22, 2020·Updated Sep 9, 2025

In Brief

A Phase 4 clinical trial evaluating Dupilumab and Placebo for Asthma. Completed, enrolled 109 participants across 65 sites in 13 countries.

Detailed Summary

Primary Objective: • To assess the effect of dupilumab on lung inflammation and related changes in airway volumes detectable by functional respiratory imaging Secondary Objective: * To evaluate the effect of dupilumab at Week 24 on bronchodynamics, hyperinflation, airway resistance, airway wall thickness, ventilation defects and mucus plugging derived from high-resolution computed tomography (HRCT) scans, patient-reported outcomes, FeNO and spirometry. * To evaluate safety of dupilumab

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesBulgaria, Denmark, France, Italy, Portugal, Romania, Saudi Arabia, Spain, Sweden, Taiwan, Ukraine, United Kingdom, United States

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedMay 22, 2020
Enrollment StartJun 20, 2020
Primary CompletionJun 26, 2023
Study CompletionAug 21, 2023
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 6.1 years ago

Interventions

Dupilumabdrug

solution for injection subcutaneous

Placebodrug

Solution for injection subcutaneous